Ultragenyx Pharmaceutical Inc. - 10 Aug 2021 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Director
Signature
/s/ Mardi C. Dier, EVP and Chief Financial Officer
Issuer symbol
ARCT
Transactions as of
10 Aug 2021
Net transactions value
-$43,631,250
Form type
4
Filing time
12 Aug 2021, 17:11:47 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARCT Common Stock Sale $40,194,000 -725,000 -33% $55.44 1,475,000 10 Aug 2021 Direct F1
transaction ARCT Common Stock Sale $3,437,250 -75,000 -5.1% $45.83 1,400,000 11 Aug 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $64.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $47.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.